Argenta Discovery in new agreement with GlaxoSmithKline
Argenta Discovery, of Harlow in the UK, has entered into a new contract research agreement with GlaxoSmithKline (GSK).
Argenta Discovery, of Harlow in the UK, has entered into a new contract research agreement with GlaxoSmithKline (GSK).
Argenta will provide discovery research capabilities to GSK's respiratory and inflammatory diseases centre of excellence for drug discovery (CEDD), based in Stevenage, UK, and to its psychiatry diseases CEDD, based in Verona, Italy.
The new agreement follows a successful collaboration undertaken during the previous 12 months.